Zacks Investment Research Lowers Pluristem Therapeutics (NASDAQ:PSTI) to Sell

Pluristem Therapeutics (NASDAQ:PSTI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Thursday, Zacks.com reports.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Shares of NASDAQ:PSTI opened at $2.83 on Thursday. Pluristem Therapeutics has a 1 year low of $2.81 and a 1 year high of $11.85. The stock’s fifty day moving average price is $3.12 and its 200-day moving average price is $3.87.

Pluristem Therapeutics (NASDAQ:PSTI) last posted its quarterly earnings data on Sunday, September 12th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.06). On average, research analysts predict that Pluristem Therapeutics will post -1.52 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. UBS Group AG increased its position in Pluristem Therapeutics by 22.2% in the first quarter. UBS Group AG now owns 20,069 shares of the biotechnology company’s stock worth $96,000 after buying an additional 3,649 shares in the last quarter. Jump Financial LLC increased its position in Pluristem Therapeutics by 57.4% in the second quarter. Jump Financial LLC now owns 33,846 shares of the biotechnology company’s stock worth $134,000 after buying an additional 12,346 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Pluristem Therapeutics in the second quarter worth about $53,000. Susquehanna International Group Ltd. purchased a new stake in Pluristem Therapeutics in the second quarter worth about $55,000. Finally, Morgan Stanley increased its position in Pluristem Therapeutics by 29.1% in the second quarter. Morgan Stanley now owns 77,014 shares of the biotechnology company’s stock worth $304,000 after buying an additional 17,368 shares in the last quarter. Institutional investors own 14.23% of the company’s stock.

About Pluristem Therapeutics

Pluristem Therapeutics, Inc is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies.

See Also: Trade War

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.